PepGen Announces New Additions to Leadership Team and Board of Directors
August 31, 2021 07:00 ET
|
PepGen, Inc.
New appointments follow PepGen’s recent $112.5 million crossover financing to advance therapies for neuromuscular diseases PepGen is rapidly advancing lead programs in Duchenne muscular dystrophy...
PepGen Announces Closing of $112.5 Million Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases
August 05, 2021 07:00 ET
|
PepGen, Inc.
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company developing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the closing of an...
PepGen Strengthens Leadership Team with SVP of Chemistry, Manufacturing & Controls and VP of Finance Appointments
June 07, 2021 09:00 ET
|
PepGen, Inc.
- Niels Svenstrup, Ph.D., will serve as Senior Vice President of Chemistry, Manufacturing & Controls - David Pelissier, CPA, will serve as Vice President of Finance - New leaders will support...